Pakistan’s Healthcare Export Boom: Pharma & Devices on the Rise

Pakistan’s pharmaceutical and medical device industry recorded a remarkable 34% export growth in 2025, marking one of the strongest performances in recent years. This surge is largely attributed to regulatory reforms introduced by the Drug Regulatory Authority of Pakistan (DRAP), which streamlined approval processes, enhanced compliance standards, and boosted international confidence in Pakistani products.

Key Drivers of Growth

  • Regulatory Reforms: DRAP’s updated framework simplified licensing, improved transparency, and aligned local standards with international benchmarks.
  • Market Expansion: Pakistani firms tapped into new markets in the Middle East, Africa, and Southeast Asia, diversifying beyond traditional buyers.
  • Quality Assurance: Enhanced compliance and stricter quality checks increased trust among foreign buyers.
  • Innovation Push: Local manufacturers invested in research and development, particularly in medical devices and generic pharmaceuticals.

Impact on Global Competitiveness

The reforms have positioned Pakistan as a reliable supplier of affordable healthcare solutions, especially in developing regions where cost-effective medicines and devices are in high demand. By meeting international standards, Pakistani exporters are now competing more effectively with established players from India, China, and Europe.

Industry Outlook

Experts predict continued growth in 2026, with opportunities in biotechnology, surgical instruments, and digital health devices. The government’s focus on export-led growth, combined with private sector innovation, is expected to sustain momentum.

Pakistan’s success story demonstrates how regulatory modernization can unlock economic potential, transforming the healthcare sector into a major contributor to national exports.